Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Assay Targets Early Lung Cancers for Adjuvant Therapy

By Labmedica International staff writers
Posted on 06 Mar 2013
Print article
A novel genetic assay helps identify patients with early, aggressive lung cancer who might benefit from adjuvant therapy.

The assay provides considerably more prognostic information than do conventional criteria as defining high-risk tumors warranting treatment that was proposed by the National Comprehensive Cancer Network (NCCN; Fort Washington, PA, USA).

The assay results were used to stratify the 269 study patients who had undergone resection of T1a node-negative and nonmetastatic, nonsquamous, non-small-cell lung cancer (NSCLC) into groups with distinctly different five-year survival rates. The novel assay assesses expression of 14 genes involved in lung cancer tumorigenesis, including ones on the epidermal growth factor receptor (EGFR)and the Kirsten ras oncogene homolog (KRAS) signaling pathways.

The assay is the only lung cancer signature to undergo blinded validation in two large cohorts from different countries, one in the United States of America and one in China. It is marketed as Pervenio Lung RS by Life Technologies (Carlsbad, CA, USA). The main study results, reported showed that the 5-year actuarial overall survival was 83%, 69%, and 52% among patients defined by the assay as low-, medium-, and high-risk groups, respectively. In multivariate analyses, relative to their counterparts in the low-risk group, patients in the intermediate-risk group had a 2.0-fold higher risk of death and patients in the high-risk group had a 3.3-fold higher risk.

The assay, which is a quantitative polymerase chain reaction (qPCR)-based, also showed good risk discrimination in analyses restricted to the smallest of tumors, those measuring 1.5 cm or less and even those measuring 1.0 cm or less. When compared with tumor size alone, the combination of the assay and tumor size significantly improved on the identification of patients who died.

Johannes R. Kratz, MD, the lead author of the study and a postdoctoral fellow at the University of California, San Francisco (CA, USA) said, “Despite the popularity and endorsement of our radiology colleagues for techniques such as stereotactic radiation for small T1aN0M0 tumors (i.e., Stage IA, no adverse features, Breslow ≤ 1 mm, T1a, no ulceration (U-), mitotic rate less than 1 mm2) , we should remember that these techniques don’t provide us with potentially important lung tissue that can provide prognostic and predictive information.” The study data was reported at Annual Meeting of the Society of Thoracic Surgeons, January 26–30, 2013, in Los Angeles (CA. USA).

Related Links:

National Comprehensive Cancer Network
Life Technologies
University of California, San Francisco



Print article

Channels

Pathology

view channel

Liver Cancer May Be Diagnosed from Altered Sugar Metabolism

Altered gene expression that causes cancerous cells to metabolize fructose differently from healthy cells could be a significant new biomarker for diagnosing liver cancer. Dietary fructose is primarily metabolized in the liver and it has now been demonstrated that, compared with normal hepatocytes, hepatocellular carcinoma... Read more

Lab Tech.

view channel

Method Preserves Microfluidic Devices for HIV Monitoring in Developing Countries

Microfluidic devices with immunochemistry have broad applications in chemotherapy monitoring, transplant patient monitoring, and especially in monitoring the efficacy of antiretroviral therapy. Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.